2022;34(1):59-74.e10
Direct answer: Blood tests may identify metabolic, kidney, electrolyte, liver, or pancreatic-enzyme changes, but they cannot rule out every GLP-1 complication
However, healthcare professionals may prescribe them off-label for weight loss
In the 2021 STEP-1 trial (1,961 adults with obesity or overweight), participants receiving semaglutide plus lifestyle intervention experienced a 14.9% mean weight loss after 68 weeks, while those on placebo lost only 2.4%
Recently, in a 6-week randomized controlled trial, we showed that the glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide is superior to bile acid sequestration (considered standard-of-care) using colesevelam in reducing BAD symptoms
There are still so many misconceptions about these medications among the general public